share_log

BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

BRIEF-TG Therapeutics Announces Publication Of Final Results From The Phase 3 Genuine Trial Evaluating Ublituximab Plus Ibrutinib In Patients With Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia In The Lancet Haematology

Brief-TG治疗公司宣布公布评估Ublituximab加Ibrutinib治疗柳叶刀血液学中复发/难治性高危慢性淋巴细胞白血病患者的第三阶段真实试验的最终结果
Reuters ·  2021/02/23 20:32

Feb 23 (Reuters) - TG Therapeutics Inc TGTX.O :

路透2月23日电-TG治疗公司TGTX.O:

* TG THERAPEUTICS ANNOUNCES PUBLICATION OF FINAL RESULTS FROM THE PHASE 3 GENUINE TRIAL EVALUATING UBLITUXIMAB PLUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IN THE LANCET HAEMATOLOGY

*TG治疗公司宣布公布评估UBLITUXIMAB加伊布鲁替尼治疗柳叶刀血液学中复发/难治性高危慢性淋巴细胞白血病患者的3期真实试验的最终结果

Source text for Eikon: Further company coverage:

Eikon的源文本:进一步的公司报道:

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发